Summary
Clonazepam (CNP) and its principal metabolite in plasma, 7-amino-CNP (ACNP), have been investigated in a prospective study of 27 newly diagnosed epileptics and correlated with specified side-effects. At a daily dose of 6 mg, the average plasma levels of both substances were about 50ng/ml, and individual values ranged from 30 to about 80ng/ml. There was a linear correlation between changes in dose and the resulting plasma levels, which indicates first order elimination kinetics. Side-effects were frequent, but neither their severity nor their occurrence could be related to plasma levels or to the rate of increase in plasma concentration of the drug. Three out of five patients who developed serious dysphoria had significantly high CNP levels. The concentration of ACNP was considerably increased in four patients who subsequently suffered from withdrawal symptoms. Drug interaction with diphenylhydantoin, i.e. decreased CNP level, was observed in all five patients who received both compounds. In general it is not yet possible to define an upper limit for the plasma levels of CNP and ACNP at which toxicity occurs. In patients treated with conventional doses of CNP, measurement of plasma concentration is not required, except in special circumstances, because of the lack of correlation between plasma level and side-effects.
Similar content being viewed by others
References
Bladin, P.: The use of clonazepam as an anticonvulsant — clinical evaluation. Med. J. Aust.1 683–688 (1973)
Edwards, V.E., Eadie, M.J.: Clonazepam, a clinical study of its effectiveness as an anticonvulsant. Proc. Austral. Ass. Neurol.10 61–66 (1973)
Elian, M., Lund, M. and Melsen, S.: The rate of dosage increase of clonazepam. Acta neurol. scand.49 suppl.53, 32–35 (1973)
Eschenhof, E.: Untersuchungen über das Schicksal des Antikonvulsivums Clonazepam im Organismus der Ratte, des Hundes und des Menschen. Arzneimittel. — Forsch.23 390–400 (1973)
Gastaut, H., Catier, J., Dravet, C., Roger, J.: Exceptional anticonvulsive properties of a new benzodiazepine. Mod. Probl. Pharmacopsychiatry: Epilepsy.4 261–269 (1970)
Ghosh, B.K.: Sequential Tests of Statistical Hypotheses. London: Addison-Wesley Publishing Company 1970
Huang, C.Y., Mc Lead, J.G., Sampson, D., Hensley, J.: Clonazepam in the treatment of epilepsy. Proc. Austral. Ass. Neurol.10 67–74 (1973)
Lehtovaara, R.: A clinical trial with clonazepam (Ro 5-4023). Acta neurol. scand.49 suppl.53, 77–81 (1973)
Lund, M. and Trolle, E.: Clonazepam in the treatment of epilepsy. Acta neurol. scand.49 suppl.53, 82–90 (1973)
Mattson, R.H. In: Antiepileptic Drugs (Ed. Woodbury, D.M., Penry, J.K. and Schmidt, R.P.), chap. 57. New York: Raven Press 1972
Mikkelsen, B., Birket-Smith, E.: A clinical study of the benzodiazepine Ro 5-4023 (clonazepam) in the treatment of epilepsy. Acta neurol. scand.49 suppl.53, 91–96 (1973)
Naestoft, J., Lund, M., Larsen, N.-E., Hvidberg, E.F.: Assay and pharmacokinetics of clonazepam in humans. Acta neurol. scand.49 suppl.53, 103–108 (1973)
Naestoft, J., Larsen, N.-E.: Quantitative determination of clonazepam and its metabolites in human plasma by gas-chromatography. J. Chromatogr.93 113–122 (1974)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sjö, O., Hvidberg, E.F., Naestoft, J. et al. Pharmacokinetics and side-effects of clonazepam and its 7- amino-metabolite in man. Eur J Clin Pharmacol 8, 249–254 (1975). https://doi.org/10.1007/BF00567123
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00567123